Home/Pipeline/AMX0114

AMX0114

Amyotrophic Lateral Sclerosis (ALS)

Phase 1Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 1

Status

Active

Company

Amylyx Pharmaceuticals

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a commercial-stage biotech focused on developing novel therapies for neurodegenerative and metabolic diseases with significant unmet medical needs. Its foundational achievement is the FDA and Health Canada approval of AMX0035 (RELYVRIO/ALBRIOZA) for ALS, secured via accelerated approval based on Phase 2 data. The company's strategy leverages a modality-agnostic R&D approach to match investigational drugs with diseases where they can have the greatest mechanistic impact, as seen in its expanding pipeline which now includes a first-in-class GLP-1 antagonist for hypoglycemia and an antisense oligonucleotide for ALS. Amylyx is transitioning from a single-product company to a diversified portfolio player while navigating the critical confirmatory trial for its lead asset.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Metabolic Disorders Rare Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active